Detection and characterization of lung cancer using cell-free DNA fragmentomes

[1]  Ash A. Alizadeh,et al.  Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition , 2020, Cell.

[2]  Song Wu,et al.  Prognostic and predictive impact of circulating tumor DNA in patients with advanced cancers treated with immune checkpoint blockade. , 2020, Cancer discovery.

[3]  Trevor J Pugh,et al.  Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab , 2020, Nature Cancer.

[4]  D. Ledbetter,et al.  Feasibility of blood testing combined with PET-CT to screen for cancer and guide intervention , 2020, Science.

[5]  D. Berry,et al.  Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  Ash A. Alizadeh,et al.  Integrating genomic features for non-invasive early lung cancer detection , 2020, Nature.

[7]  S. J. Henley,et al.  Screening for Lung Cancer — 10 States, 2017 , 2020, MMWR. Morbidity and mortality weekly report.

[8]  Harry J de Koning,et al.  Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial. , 2020, The New England journal of medicine.

[9]  R. Scharpf,et al.  White blood cell and cell-free DNA analyses for detection of residual disease in gastric cancer , 2020, Nature Communications.

[10]  H. Aburatani,et al.  Comparative analysis of TTF‐1 binding DNA regions in small‐cell lung cancer and non‐small‐cell lung cancer , 2019, Molecular Oncology.

[11]  M. Schimek,et al.  Inference of transcription factor binding from cell-free DNA enables tumor subtype prediction and early detection , 2019, Nature Communications.

[12]  H. Nielsen,et al.  Genome-wide cell-free DNA fragmentation in patients with cancer , 2019, Nature.

[13]  R. Scharpf,et al.  Early Noninvasive Detection of Response to Targeted Therapy in Non-Small Cell Lung Cancer. , 2019, Cancer research.

[14]  P. Massion,et al.  Biomarkers in Lung Cancer Screening: Achievements, Promises, and Challenges. , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[15]  Jae Ho Lee,et al.  Role of Low‐Dose Computerized Tomography in Lung Cancer Screening among Never‐Smokers , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[16]  R. Scharpf,et al.  Dynamics of Tumor and Immune Responses during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer. , 2018, Cancer research.

[17]  D M Parkin,et al.  Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods , 2018, International journal of cancer.

[18]  J. McPherson,et al.  Sensitive tumour detection and classification using plasma cell-free DNA methylomes , 2018, Nature.

[19]  S. Hanash,et al.  Assessment of Lung Cancer Risk on the Basis of a Biomarker Panel of Circulating Proteins , 2018, JAMA oncology.

[20]  R. Munden,et al.  The epidemiology of lung cancer. , 2018, Translational lung cancer research.

[21]  S. Hanash,et al.  Blood based biomarkers beyond genomics for lung cancer screening. , 2018, Translational lung cancer research.

[22]  Wulin Shen,et al.  Clinical significance of combined detection of interleukin-6 and tumour markers in lung cancer , 2018, Autoimmunity.

[23]  Jia Gu,et al.  fastp: an ultra-fast all-in-one FASTQ preprocessor , 2018, bioRxiv.

[24]  T. Hughes,et al.  The Human Transcription Factors , 2018, Cell.

[25]  Nikhil Wagle,et al.  Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors , 2017, Nature Communications.

[26]  Charles A Powell,et al.  Evaluating Molecular Biomarkers for the Early Detection of Lung Cancer: When Is a Biomarker Ready for Clinical Use? An Official American Thoracic Society Policy Statement , 2017, American journal of respiratory and critical care medicine.

[27]  Ahmedin Jemal,et al.  Lung Cancer Screening With Low-Dose Computed Tomography in the United States—2010 to 2015 , 2017, JAMA oncology.

[28]  Sam Angiuoli,et al.  Direct detection of early-stage cancers using circulating tumor DNA , 2017, Science Translational Medicine.

[29]  Jin-liang Kong,et al.  Serum tumor-associated autoantibodies as diagnostic biomarkers for lung cancer: A systematic review and meta-analysis , 2017, PloS one.

[30]  Ashwini Naik,et al.  Phylogenetic ctDNA analysis depicts early stage lung cancer evolution , 2017, Nature.

[31]  A. Bankier,et al.  Guidelines for Management of Incidental Pulmonary Nodules Detected on CT Images: From the Fleischner Society 2017. , 2017, Radiology.

[32]  S. Elledge,et al.  Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy , 2017, Science.

[33]  Luc Girard,et al.  ASCL1 and NEUROD1 Reveal Heterogeneity in Pulmonary Neuroendocrine Tumors and Regulate Distinct Genetic Programs. , 2016, Cell reports.

[34]  Jie He,et al.  Epidemiology of Lung Cancer. , 2016, Surgical oncology clinics of North America.

[35]  Hongbing Shen,et al.  Genomic Landscape Survey Identifies SRSF1 as a Key Oncodriver in Small Cell Lung Cancer , 2016, PLoS genetics.

[36]  M. Roobol,et al.  Compliance Rates with the Prostate Cancer Research International Active Surveillance (PRIAS) Protocol and Disease Reclassification in Noncompliers. , 2015, European urology.

[37]  P. Pinsky.  Principles of Cancer Screening. , 2015, The Surgical clinics of North America.

[38]  G. Silvestri,et al.  A Bronchial Genomic Classifier for the Diagnostic Evaluation of Lung Cancer. , 2015, The New England journal of medicine.

[39]  Martin Vingron,et al.  Comprehensive genomic profiles of small cell lung cancer , 2015, Nature.

[40]  Edwin Cuppen,et al.  Sambamba: fast processing of NGS alignment formats , 2015, Bioinform..

[41]  Steven J. M. Jones,et al.  Comprehensive molecular profiling of lung adenocarcinoma , 2014, Nature.

[42]  D. de Ruysscher,et al.  Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[43]  S. Raoof,et al.  A practical algorithmic approach to the diagnosis and management of solitary pulmonary nodules: part 2: pretest probability and algorithm. , 2013, Chest.

[44]  S. Raoof,et al.  A practical algorithmic approach to the diagnosis and management of solitary pulmonary nodules: part 1: radiologic characteristics and imaging modalities. , 2013, Chest.

[45]  Timothy R Church,et al.  Selection criteria for lung-cancer screening. , 2013, The New England journal of medicine.

[46]  G. Parmigiani,et al.  Detection of Chromosomal Alterations in the Circulation of Cancer Patients with Whole-Genome Sequencing , 2012, Science Translational Medicine.

[47]  Steven J. M. Jones,et al.  Comprehensive genomic characterization of squamous cell lung cancers , 2012, Nature.

[48]  J. Sørensen,et al.  Carcinoembryonic antigen (CEA) as tumor marker in lung cancer. , 2012, Lung cancer.

[49]  Steven L Salzberg,et al.  Fast gapped-read alignment with Bowtie 2 , 2012, Nature Methods.

[50]  Y. Benjamini,et al.  Summarizing and correcting the GC content bias in high-throughput sequencing , 2012, Nucleic acids research.

[51]  C. Gatsonis,et al.  Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening , 2012 .

[52]  Xavier Robin,et al.  pROC: an open-source package for R and S+ to analyze and compare ROC curves , 2011, BMC Bioinformatics.

[53]  J. Goedert,et al.  C-reactive protein and risk of lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  S Senan,et al.  Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[55]  E. Felip,et al.  Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[56]  Aaron R. Quinlan,et al.  Bioinformatics Applications Note Genome Analysis Bedtools: a Flexible Suite of Utilities for Comparing Genomic Features , 2022 .

[57]  K. Havemann,et al.  [Carcinoembryonic antigen (CEA) in patients with lung cancer: correlation with tumour extent and response to treatment (author's transl)]. , 1977, Deutsche medizinische Wochenschrift.

[58]  M. Coleman,et al.  Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE--5-a population-based study. , 2014, The Lancet. Oncology.

[59]  Paul Fockens,et al.  Participation and yield of colonoscopy versus non-cathartic CT colonography in population-based screening for colorectal cancer: a randomised controlled trial. , 2012, The Lancet. Oncology.

[60]  Callum G Fraser,et al.  Use of faecal markers in screening for colorectal neoplasia: a European group on tumor markers position paper , 2011, International journal of cancer.

[61]  W. Klepetko,et al.  Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.